US 12,202,845 B2
Ras inhibitors
John E. Knox, Emerald Hills, CA (US); Elena S. Koltun, Foster City, CA (US); Yang Liu, Foster City, CA (US); G. Leslie Burnett, Redwood City, CA (US); James Cregg, Belmont, CA (US); Anne V. Edwards, San Mateo, CA (US); Adrian L. Gill, Atherton, CA (US); Andreas Buckl, San Francisco, CA (US); and Christopher Semko, Fremont, CA (US)
Assigned to Revolution Medicines, Inc., Redwood City, CA (US)
Filed by Revolution Medicines, Inc., Redwood City, CA (US)
Filed on Oct. 7, 2022, as Appl. No. 17/938,890.
Claims priority of provisional application 63/254,013, filed on Oct. 8, 2021.
Prior Publication US 2023/0303591 A1, Sep. 28, 2023
Int. Cl. C07D 519/00 (2006.01); A61P 35/00 (2006.01)
CPC C07D 519/00 (2013.01) [A61P 35/00 (2018.01); C07B 2200/05 (2013.01)] 6 Claims
 
1. A compound having the structure of Formula I:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof,
wherein A is morpholine-diyl;
X1, X2, and X3 are each CH2;
m is 1;
n is 1;
R1 is hydrogen, optionally substituted C1-C6 heteroalkyl, or optionally substituted 3 to 10-membered heterocycloalkyl;
R2 is optionally substituted C1-C6 alkyl; and
R3 is cyclopentyl.